<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01874639</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0156</org_study_id>
    <nct_id>NCT01874639</nct_id>
  </id_info>
  <brief_title>Use of Transcollation Device to Decrease Blood Loss During Hepatic Resections: a Randomized Cohort Study (HEPACOLL)</brief_title>
  <official_title>Use of Transcollation Device to Decrease Blood Loss During Hepatic Resections: a Randomized Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>INNOPATH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MEDTRONIC labs provide the aquamantys® probes for the study.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      Blood loss in hepatic surgery is the main factor of postoperative morbidity. The use of the&#xD;
      most effective possible tool for hemostasis allows a bleeding decrease during liver&#xD;
      transection and thus could reduce postoperative morbidity.&#xD;
&#xD;
      In the past decade, the improvement of techniques of transection of the hepatic parenchyma&#xD;
      was one of the most important factors to ensure the hepatectomy safety. But the clinical&#xD;
      performances of these technological innovations (ultrasound dissectors, monopolar&#xD;
      radiofrequency probes and dissection devices using pressurized water) remain still unclear.&#xD;
&#xD;
      The medical device of hemostasis Aquamantys® (Salient company, Innopath) use the technology&#xD;
      of &quot;transcollation&quot; combining a source of radiofrequency associated with a conductive liquid&#xD;
      (NaCl 0.9% solution). The system consists of a specific generator (Aquamantys Pump&#xD;
      Generator®) and single-use probes (Aquamantys 2.3 BipolarSealer®). The energy of&#xD;
      radiofrequency is delivered by two bipolar electrodes. The innovative aspect of this device&#xD;
      consists in maintaining the tissue to a temperature of 100°C, while using a conductive liquid&#xD;
      which acts as process of cooling and avoids the drying out of tissues, smoke, risks of&#xD;
      electric arc and overheating met with conventional electrosurgery. This device allows the&#xD;
      coagulation of blood vessels but also bile ducts. The Aquamantys® system could decrease the&#xD;
      postoperative morbidity and mortality due to a decrease of blood loss and biliary leak. These&#xD;
      clinical benefits could be translated by an improvement of the direct and indirect costs&#xD;
      associated to the surgery. However the Aquamantys® technology has not been scientifically&#xD;
      validated in the context of the hepatic surgery, and this technology is expensive due to the&#xD;
      purchase of single-use bipolar probes (Aquamantys 2.3 BipolarSealer®) and to the investment&#xD;
      in a generator (Aquamantys Pump Generator®).&#xD;
&#xD;
      Consequently, it is essential to realize a study measuring the clinical and medical economic&#xD;
      impact of the transcollation technology (Aquamantys® device) in the hepatic surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After validation of the inclusion and exclusion criteria, the patients include in this&#xD;
      clinical trial will be randomized between the two arms of the study:&#xD;
&#xD;
        -  Control group: hepatectomy with conventional hemostasis using standard bipolar&#xD;
           coagulation&#xD;
&#xD;
        -  Test group: hepatectomy with Aquamantys®&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood loss during surgery</measure>
    <time_frame>at day 0</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of liver transection</measure>
    <time_frame>at day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of surgery</measure>
    <time_frame>at day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of red blood cells transfusions</measure>
    <time_frame>at day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of frozen plasma transfusions</measure>
    <time_frame>at day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of crystalloid and colloid fluids</measure>
    <time_frame>at day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need of norepinephrine during the surgery</measure>
    <time_frame>at day 0</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Hepatectomy</condition>
  <arm_group>
    <arm_group_label>hepatectomy ( conventional hemostasis )</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:&#xD;
- Control group: hepatectomy with conventional hemostasis using standard bipolar coagulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hepatectomy with Aquamantys</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:&#xD;
- Test group: hepatectomy with Aquamantys®</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>standard bipolar coagulation</intervention_name>
    <arm_group_label>hepatectomy ( conventional hemostasis )</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aquamantys® probe for liver hemostasis</intervention_name>
    <arm_group_label>hepatectomy with Aquamantys</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing elective surgery for liver resection of malignant or benign&#xD;
             disease&#xD;
&#xD;
          -  Hepatic resection of two or more segments&#xD;
&#xD;
          -  No coagulation disorder&#xD;
&#xD;
          -  No portal hypertension (platelets ≥ 100 G/L, absence of splenomegaly, absence of&#xD;
             portal hypertension varices)&#xD;
&#xD;
          -  Obtaining the patient's written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years and &gt; 80 years&#xD;
&#xD;
          -  ASA score &gt; 3&#xD;
&#xD;
          -  Cirrhosis, liver fibrosis &gt; F2, steatosis &gt; 60%, sinusoidal obstruction syndrome&#xD;
&#xD;
          -  Cognitive troubles and major disability making impossible to understand the study and&#xD;
             signed the informed consent (e.g. dementia, psychiatric disorders like psychosis,&#xD;
             speech disorder ...)&#xD;
&#xD;
          -  Liver and kidney failure&#xD;
&#xD;
          -  Pregnancy and lactating women&#xD;
&#xD;
          -  Legal incapacity&#xD;
&#xD;
          -  Patients already enrolled in a clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel BUC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick LACARIN</last_name>
    <phone>04 73 75 11 95</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>04 73 75 11 95</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>June 7, 2013</study_first_submitted>
  <study_first_submitted_qc>June 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2013</study_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatectomy</keyword>
  <keyword>blood loss</keyword>
  <keyword>hemostasis</keyword>
  <keyword>coagulation</keyword>
  <keyword>Liver surgery (benign or malign)</keyword>
  <keyword>Resection of 2 or more segments</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

